Updates are available Correction dated 2020-09-25

Article History

Received: 5 June 2020

Accepted: 8 August 2020

First Online: 18 August 2020

Change Date: 25 September 2020

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10620-020-06613-8

Compliance with Ethical Standards

:

: TC, FD, CZ, and NM have no conflict of interest to disclose. LPB reports personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance; grants from AbbVie, MSD, Takeda; stock options: CTMA.